Get the Stockscreener App
2.21
9.43%
-0.23
Pre-market:
2.10
-0.11
-4.98%
Mainz Biomed N V stock is traded at $2.21, with a volume of 120.29K.
It is down -9.43% in the last 24 hours and down -31.37% over the past month.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
See More
Previous Close:
$2.44
Open:
$2.32
24h Volume:
120.29K
Relative Volume:
0.57
Market Cap:
$6.72M
Revenue:
$895.50K
Net Income/Loss:
$-26.30M
P/E Ratio:
-1.3476
EPS:
-1.64
Net Cash Flow:
$-23.84M
1W Performance:
-12.99%
1M Performance:
-31.37%
6M Performance:
-74.84%
1Y Performance:
-91.87%
1-Day Range:
$2.18
$2.43
1-Week Range:
$2.18
$2.57
52-Week Range:
$2.18
$40.40
Mainz Biomed N V Stock (MYNZ) Company Profile
Name
Mainz Biomed N V
Sector
Industry
Phone
-
Address
-
Compare MYNZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYNZ
Mainz Biomed N V
|
2.21 | 7.72M | 895.50K | -26.30M | -23.84M | -1.64 |
|
TMO
Thermo Fisher Scientific Inc
|
413.92 | 163.30B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
196.41 | 143.73B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
521.68 | 40.98B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
113.44 | 32.94B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
143.54 | 27.01B | 15.50B | 1.33B | 2.16B | 7.34 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Initiated | Maxim Group | Buy |
| Nov-25-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-21-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-21-22 | Initiated | H.C. Wainwright | Buy |
Mainz Biomed N V Stock (MYNZ) Latest News
Maxim Group to Act as Sole Placement Agent for MYNZ Offering | M - GuruFocus
Mainz Biomed Announces Pricing of $4 Million Follow-On Offering and Warrant Amendments - Nasdaq
Cancer Detection Company Mainz Biomed Raises Fresh $4M: Key Details of Share and Warrant Offering - Stock Titan
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants - GlobeNewswire
Mainz Biomed stock plunges to 52-week low of $2.18 amid market challenges - Investing.com
Trend Tracker for (MYNZ) - news.stocktradersdaily.com
Mainz Biomed to update on CRC screening study by end of summer - Investing.com South Africa
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study - GlobeNewswire
Mainz Biomed Plans Interim Readout For EAArly DETECT 2 CRC Study - Nasdaq
Revolutionary Cancer Prevention: Mainz Biomed Combines AI and mRNA in 2,000-Patient Colorectal Screening Trial - Stock Titan
Mainz Biomed to hold annual meeting on June 2 - Investing.com Australia
Mainz Biomed to hold annual meeting on June 2 By Investing.com - Investing.com Canada
Mainz Biomed Prepares for June 2025 Annual General Meeting - TipRanks
Stocks of Mainz Biomed N.V (MYNZ) are poised to climb above their peers - Sete News
Investing in Mainz Biomed N.V (MYNZ): What You Must Know - knoxdaily.com
Mainz Biomed Enters into Technology Partnership with EDX Medical Group - MSN
MYNZ Partners with EDX Medical to Enhance Diagnostic Offerings i - GuruFocus
Strategic Partnership: Mainz Biomed and EDX Medical Join Forces to Transform Early Cancer Detection in UK Market - Stock Titan
Mainz Biomed (MYNZ) Sees Revenue Surge Amid Strong Demand for Co - GuruFocus
Mainz Biomed N.V (NASDAQ: MYNZ) Is Expected To Soar To Higher Prices In The Months To Come. - Marketing Sentinel
Mainz Biomed advances in FDA approval for CRC test By Investing.com - Investing.com South Africa
Mainz Biomed advances in FDA approval for CRC test - Investing.com Australia
The Mainz Biomed N.V (MYNZ) Stock Is Headed for a Correction - uspostnews.com
MYNZ: Mainz Biomed Advances Cancer Detection with New Feasibilit - GuruFocus
Mainz Biomed N.V. Reports Q1 2025 Accomplishments and FDA Premarket Approval Progress - Nasdaq
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval - GlobeNewswire
Mainz Biomed's Game-Changing Cancer Test Shows 98% Accuracy as Company Expands European Presence - Stock Titan
Mainz Biomed (NASDAQ:MYNZ) Short Interest Down 48.7% in April - Defense World
Mainz Biomed (MYNZ) Sees Revenue Surge Amid Strong Demand for ColoAlert - GuruFocus
Long Term Trading Analysis for (MYNZ) - news.stocktradersdaily.com
Mainz Biomed (NASDAQ:MYNZ) Trading Up 3.9% – What’s Next? - Defense World
Colorectal to Pancreatic: Mainz Biomed Expands Reach in Early Cancer Detection - Markets Herald
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update - ADVFN
(MYNZ) Investment Report - news.stocktradersdaily.com
Mainz BioMed's Trial To Bring Critical Early Cancer Detection One Step Closer - Benzinga
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Mainz Biomed Reports 2024 Financial Success and Strategic Advances - TipRanks
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire Inc.
Virtu Financial LLC Takes $79,000 Position in Mainz Biomed (NASDAQ:MYNZ) - Defense World
Mainz Biomed (MYNZ) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Mainz Biomed begins pivotal colorectal cancer test study By Investing.com - Investing.com Canada
Mainz Biomed Enrolls First Patient In EAArly DETECT 2 Study To Advance Colorectal Cancer Test - Nasdaq
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study - The Manila Times
Mainz Biomed begins pivotal colorectal cancer test study - Investing.com
Revolutionary AI-Powered Cancer Test: Mainz Biomed Begins Major Clinical Trial - Stock Titan
(MYNZ) Proactive Strategies - Stock Traders Daily
Mainz Biomed N V Stock (MYNZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):